logo
Eating Food in This Order Can Have Similar Benefits to Ozempic

Eating Food in This Order Can Have Similar Benefits to Ozempic

Yahoo13-03-2025

By now, you likely know which foods and drinks can help prevent Type 2 diabetes—but did you know that the order in which you eat them can make a big difference in improving blood sugar and boosting your GLP-1 production (and weight loss!), too?
Well, now you do. Or at least you will if you keep reading.
🩺 SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week 💊
But first, some backstory: I first learned about the food order phenomeon from French microbiologist Jessie Inchauspé (who you might know as @glucosegoddess on Instagram). The author of several books and cookbooks on the theme of stabilizing blood sugar, most of which I own and have read front to back (I recommend The Glucose Goddess Method), she's known for sharing easy-to-DIY blood sugar hacks for her readers and followers to implement in everyday life.
One of the most popular? Eating food in a specific order, which wasn't her idea alone: Several studies conducted over the past decade have found that the sequence in which you eat your foods can impact your blood sugar, insulin, and GLP-1 levels and production. This exciting, because that's also what GLP-1 medications like Ozempic and Wegovy do.
Parade aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission.
Related:
Published in the journal Diabetes Care, a 2015 study had 16 individuals with Type 2 diabetes eat the same meal for three days—but in different orders each time. For the first day, they had carbohydrates first, followed by proteins and vegetables. On the second day, they ate protein and vegetables first, consuming carbs afterwards. For the the last meal of the study, they ate three elements—carbs, protein, and vegetables—altogether.
After measuring glucose, insulin and other related hormonal responses, the study found that participants who ate carbs last produced higher levels of GLP-1 and lower levels of insulin while demonstrating a 53% over all reduction in blood sugar levels after eating as compared to eating carbs first.
Multiple studies have since replicated these findings—published in BMJ Open Diabetes Research & Care and Nutrients, respectively—but the most most recent was published in Diabetes Care in February 2025. Led by yet another group of researchers at Weill Cornell Medicine, they found that the carbs-last approach was associated with 44% lower sugar peaks compared with eating carbs first.
Ending with carbs last helped stabilize participants' glucose levels, reducing glycemic variability by 16.5%, and even aided in unintentional weight loss: Participants lost an average of 4.3 pounds in 12 days despite not making changes to their caloric intake.
TL;DR? Eat your fiber-rich veggies and proteins first—so start with a salad with chicken or tofu, for example—then eat your carbs (rice, pasta, potatoes, bread). Your blood sugar, insulin and GLP-1 levels will thank you.
Related:
As for why or how food order could possibly have this effect? Basically, fiber-rich vegetables take longer to digest, which forms a protective "barrier" in your stomach. This slows the breakdown and absorption of carbohydrates, preventing blood sugar spikes and crashes and therefore increasing GLP-1. (This is also why increasing fiber is often recommended for blood sugar control. Fiber is great for it!)
Alternatively, when you eat carbs first, your body quickly converts them into glucose, resulting in a surge of insulin to manage the sugar rush. Eating protein and fiber first reduces the need for that huge insulin response, making blood sugar more stable over time. The less blood sugar spikes you have means more sustained levels of GLP-1. I know this is probably confusing, but basically, fiber likes to go first in the gut.
Related:
You don't need to have Type 2 diabetes to reap the benefits of this food sequence: One of the aforementioned studies saw a 40% reduction in post-meal blood sugar peaks when eating carbs first as compared to last in people with prediabetes. This means they had high blood sugar, but not high enough to be considered Type 2 diabetes.
Translation? Yes, the benefits seem to apply whether or not you're diabetic. So go eat that salad (first)!
Related:
As for why this matters? This information provides a simple, practical and most importantly, sustainable solution for everyday blood sugar control that almost anyone can follow. Plus, there's no medication required.
"We're always looking for ways to help people with diabetes lower their blood sugar," said , who served as the 2015 study's senior author and principal investigator. "We rely on medicine, but diet is an important part of this process, too. Unfortunately, we've found that it's difficult to get people to change their eating habits."
Also the Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College and director the Comprehensive Weight Control Center (both at the time of the study and in present day), Dr. Aronne continued: "Carbohydrates raise blood sugar, but if you tell someone not to eat them—or to drastically cut back—it's hard for them to comply. This study points to an easier way that patients might lower their blood sugar and insulin levels."
Thus, rather than telling people to completely cut out one type of food, they can simply modify how they're eating it—and hopefully get some Ozempic-like perks while they're at it.
Up Next:"Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes." BMJ open diabetes research & care.
"A Randomized Controlled Pilot Study of the Food Order Behavioral Intervention in Prediabetes." Nutrients.
"Carbohydrates-Last Food Order Improves Time in Range and Reduces Glycemic Variability." Diabetes care.
Dr. Louis J. Aronne, MD, FACP, Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College and director the Comprehensive Weight Control Center
"Food order has significant impact on glucose and insulin levels." Weill Cornell Medicine.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says
Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says

Medscape

time19 minutes ago

  • Medscape

Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says

(Reuters) -Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said on Friday. In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (NAION). But this is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. NAION is the second-most common cause of blindness due to optic nerve damage, after glaucoma. "This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns," said Barclays analyst Emily Field. U.S.-listed shares of the Danish drugmaker were up nearly 2.5% in early trading. The EMA, which started its review in December, has asked Novo to add NAION as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The "benefit-risk profile of semaglutide remains favorable," the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust CEO Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about $150 billion by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing NAION by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing NAION more than doubled after two years of treatment with Ozempic, compared to patients taking medicines from other classes. The U.S. Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. (Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)

The $1.3 Billion Health-Tech IPO Everyone Missed--Until It Soared 21% on Day One
The $1.3 Billion Health-Tech IPO Everyone Missed--Until It Soared 21% on Day One

Yahoo

time20 minutes ago

  • Yahoo

The $1.3 Billion Health-Tech IPO Everyone Missed--Until It Soared 21% on Day One

Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That move gives the digital chronic-care startup a market cap of roughly $1.3 billion. The $150 million raise was more than just well receivedinvestor demand came in more than 15x oversubscribed, with most allocations going to a concentrated group of institutional buyers. It's another sign that appetite for health-tech IPOs is heating up again. U.S. listings have raised nearly $25 billion year-to-date, and early-stage healthcare names are up an average of 18% since listing. Founded in 2011, Omada offers virtual care between doctor visitsfocused on diabetes, obesity, hypertension, and joint pain. What sets it apart? It's not chasing the GLP-1 gold rush. Instead, Omada supports people already on those drugs, helping them manage side effects, nutrition, and post-treatment maintenance. About 50,000 of its 679,000 members are on GLP-1s. CEO Sean Duffy told Bloomberg that while AI powers much of the back-end, real human interaction is what drives results. Our members tell us they want a personand I have yet to see anyone that feels accountable to ChatGPT, he said. Revenue for Q1 2025 came in just under $55 millionup from $35.1 million a year agowhile net losses narrowed by more than half to $9.4 million. That improving financial picture, combined with a clear niche in chronic care, could be what's drawing top-tier investors. Revelation Partners, Andreessen Horowitz, Fidelity, and USVP are all among the largest shareholders. The IPO was led by Morgan Stanley, Goldman Sachs, and JPMorgan. OMDA now trades on the Nasdaq Global Marketand it's one more sign that digital health might be staging a real comeback. This article first appeared on GuruFocus.

Should You Invest $1,000 in Eli Lilly today?
Should You Invest $1,000 in Eli Lilly today?

Yahoo

timean hour ago

  • Yahoo

Should You Invest $1,000 in Eli Lilly today?

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight loss market could represent a multibillion-dollar opportunity well into the next decade. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow earnings over time. But, in recent years, one particular product portfolio has stood out and driven double-digit revenue growth: drugs to help people lose weight. Right now, Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss, though doctors have prescribed either one for patients hoping to shed pounds. Mounjaro and Zepbound each have become blockbusters, bringing in billion-dollar revenue annually. Lilly dominates the weight loss market along with rival Novo Nordisk, but a recent move by Lilly could help it push farther ahead in the coming years. Considering this, should you invest $1,000 in Lilly stock today? Let's find out. So, first, let's talk about Lilly's path so far in this market and what might lie ahead. Lilly's weight loss drugs are part of a class known as dual GIP and GLP-1 receptor agonists. They act on hormonal pathways involved in the digestion process and help control blood sugar levels and appetite. Novo Nordisk's rival drug, semaglutide -- sold as Ozempic for type 2 diabetes and Wegovy for weight loss -- targets only GLP-1 but works in a similar way. Novo Nordisk was first to market with its product, winning approval for Ozempic in 2017, and this offered it time to build a market-leading position. But demand has been so high for such weight loss drugs that Lilly quickly gained share soon after entering the market with Mounjaro in 2022 and then with Zepbound in 2023. In fact, demand has been so strong that these drugs held spots on the U.S. Food and Drug Administration's drug shortage list for quite some time, only exiting the list in recent months. A better supply situation for weight loss drugs isn't due to a drop in demand but instead to increases in manufacturing capacity by both companies. So solid demand for these products still exists -- and is likely to grow. It's important to keep in mind, though, that both Lilly and rivals may face some headwinds in the years to come, and that's why Goldman Sachs Research recently reduced its forecast for global sales of anti-obesity medicines to $95 billion by 2030, from an earlier forecast of $130 billion. This is due to several potential challenges, including lower per-unit prices and weaker reimbursement from certain insurers. But even considering the challenges, "we see a significant growth opportunity for both existing players as well as new entrants into this market," said Goldman analyst Asad Haider. After all, from today's $28 billion market, the forecast figure represents a 239% increase. A look at Lilly's weight loss drug sales shows us this company has the momentum to benefit from this high-growth market. Last year, Mounjaro and Zepbound generated more than $11 billion and $4.9 billion in sales, respectively. And these two products are driving double-digit total sales growth at Lilly -- with a 32% gain in the full year and a 45% gain in the most recent quarter. Now, what may push Lilly past Novo Nordisk -- and keep it far ahead of newer rivals down the road -- is the company's progress on an oral weight loss candidate. Current products are in injectable form, which may be less convenient and even uncomfortable for certain users. Lilly recently reported positive results from a phase 3 trial of its oral candidate, orforglipron, and plans to request approval for use in weight management by the end of the year. Though Novo Nordisk sells an oral form of semaglutide, it involves strict food and water guidelines. The potential Lilly product doesn't, offering it a significant advantage. Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies such as Amazon and Nvidia, also known for delivering double-digit revenue growth. In fact, since the launch of tirzepatide, Lilly has traded at valuations resembling those of growth stocks. So it may seem pricey to you for a pharmaceutical player. But it's worth keeping in mind that Lilly stands out from the pharma crowd due to its presence in the high-growth market of weight loss drugs, yet at the same time it offers you the stability and dividend growth of a pharma stock. You generally can count on big pharma companies for steady revenue since patients always need their medicines -- regardless of the economic situation. And you can count on Lilly for passive income too, with a forward dividend of $6, representing a dividend yield of 0.8%. Meanwhile, valuation has come down from its peak to levels that look very acceptable for a growth stock. All of this means that, by investing in Lilly, you're getting growth worthy of a tech company along with the safety generally associated with a pharma stock. That makes the stock well worth the price, and a great place to park $1,000 right now. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Goldman Sachs Group, and Nvidia. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Should You Invest $1,000 in Eli Lilly today? was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store